Skip to main content

Table 4 Treatment-emergent adverse events reported in ≥5 % of subjects in the teduglutide group

From: A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects

Variable, n (%) Placebo (n = 13) Teduglutide 4 mg (n = 23)
Treatment-emergent AEs 9 (69) 14 (61)
Abdominal distention 2 (15) 8 (35)
Constipation 2 (15) 5 (22)
Headache 2 (15) 5 (22)
Abdominal pain 1 (8) 5 (22)
Nausea 0 5 (22)
Dyspepsia 0 2 (9)
Eructation 0 2 (9)
Extremity pain 0 2 (9)
  1. AE = adverse event.